Successes and Failures for Drugs in Late-Stage Development for Alzheimer’s Disease
To date, symptomatic medications prevail as the mainstay of treatment options for Alzheimer’s disease (AD). There have been tremendous investments made to increase the numbers of drugs approved and the targets engaged, in an effort to alter the disease course or pathophysiology of AD. Unfortunately, almost all studies have not met expectations and no new drug (beyond medical foods) has been approved for the treatment of AD in the last decade. This review is a comparison of novel AD therapies in the late phases of clinical testing, including recent high-profile clinical failures, and agents in development with relatively unexplored mechanisms of action, with a focus on their potential as therapeutic agents and their proposed advantages over the treatments currently in use.
KeywordsTranscranial Magnetic Stimulation Mini Mental State Examination Score BACE Inhibitor Gamma Secretase Masitinib
Supported by the Banner Sun Health Research Institute, NIA P30 AG 019610 and the Arizona Alzheimer’s Research Consortium.
Camryn Berk has no disclosures relating to this manuscript. Dr Sabbagh receives contract/grant support from Lilly, Avanir, Pfizer, Eisai, Functional Neuromodulation, Genentech, Piramal, Avid and Elan. Dr Sabbagh is an advisor/consultant to Biogen, Piramal and Eisai. Dr Sabbagh receives royalties from Wiley and TenSpeed. Neither author received compensation in the drafting of this manuscript.
- 2.Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology. 1991;41(4):479–86.CrossRefPubMedGoogle Scholar
- 8.Landhuis L. Will tau drug show its true colors in phase 3 trials? Alzheimer Res Forum. October 2, 2012. http://www.alzforum.org/new/detail.asp?id=3283#ClaudeWischik.
- 12.Pfizer. Amyloid imaging and safety study of subcutaneous bapineuzumab in subjects with mild to moderate Alzheimer’s disease (SUMMIT AD). NCT01254773.Google Scholar
- 14.Goto T, Fujikoshi S, Uenaka K, et al. Solanezumab was safe and well-tolerated for Asian patients with mild-to-moderate Alzheimer’s disease in a multicenter, randomized, open-label, multi-dose study. Alzheimers Dement. 2012;6(4 Suppl):S308.Google Scholar
- 16.Wilkinson K, El Khoury J. Microglial scavenger receptors and their roles in the pathogenesis of Alzheimer’s disease. Int J Alzheimer’s Dis. 2012;2012:Article ID 489456.Google Scholar
- 46.Smith G, Laxton A, Tang-Wai D, et al. Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer disease. Arch Neurol. 2012;69(9):1141-8.Google Scholar